Download Files:
Halopemide
SKU
HY-119093-1 mg
Category Reference compound
Tags Cancer; Neurological Disease, Dopamine Receptor;Phospholipase, GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling
$64 – $1,330
Products Details
Product Description
– Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent[1][2].
Web ID
– HY-119093
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C21H22ClFN4O2
References
– [1]Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17.|[2]Neale R, et al. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the “antidyskinetic” drugs, oxiperomide and tiapride. Psychopharmacology (Berl). 1981;75(3):254-7.|[3]Skafi N, et al. Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. J Cell Physiol. 2019 Apr;234(4):4825-4839.
CAS Number
– 59831-65-1
Molecular Weight
– 416.88
Compound Purity
– 99.65
SMILES
– O=C(C1=CC=C(C=C1)F)NCCN2CCC(CC2)N3C4=CC=C(C=C4NC3=O)Cl
Clinical Information
– No Development Reported
Research Area
– Cancer; Neurological Disease
Solubility
– DMSO : 41.67 mg/mL (ultrasonic)
Target
– Dopamine Receptor;Phospholipase
Isoform
– D1 Receptor;D2 Receptor;PLD
Pathway
– GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.